Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, Hurd DD, Cashen AF, Blum KA, Goy A, Fenske TS, Wagner-Johnston ND, Carson K, Siegel MJ, Russler-Germain D, Schneider SE, Mehta-Shah N, Kahl B, Bartlett NL. Fehniger TA, et al. Haematologica. 2024 Mar 1;109(3):953-957. doi: 10.3324/haematol.2022.282246. Haematologica. 2024. PMID: 37706336 Free PMC article. Clinical Trial. No abstract available.
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Shah NM, Kahl BS. Patel DA, et al. Among authors: fehniger ta. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):552-560. doi: 10.1016/j.clml.2023.04.003. Epub 2023 Apr 24. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37183115
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
Wong P, Foltz JA, Chang L, Neal CC, Yao T, Cubitt CC, Tran J, Kersting-Schadek S, Palakurty S, Jaeger N, Russler-Germain DA, Marin ND, Gang M, Wagner JA, Zhou AY, Jacobs MT, Foster M, Schappe T, Marsala L, McClain E, Pence P, Becker-Hapak M, Fisk B, Petti AA, Griffith OL, Griffith M, Berrien-Elliott MM, Fehniger TA. Wong P, et al. Among authors: fehniger ta. J Clin Invest. 2023 Jul 3;133(13):e162530. doi: 10.1172/JCI162530. J Clin Invest. 2023. PMID: 37279078 Free PMC article.
Single-cell T-cell receptor repertoire profiling in dogs.
Hoang MH, Skidmore ZL, Rindt H, Chu S, Fisk B, Foltz JA, Fronick C, Fulton R, Zhou M, Bivens NJ, Reinero CN, Fehniger TA, Griffith M, Bryan JN, Griffith OL. Hoang MH, et al. Among authors: fehniger ta. Commun Biol. 2024 Apr 22;7(1):484. doi: 10.1038/s42003-024-06174-w. Commun Biol. 2024. PMID: 38649520 Free PMC article.
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.
de Jonge PKJD, van Hauten PMM, Janssen LD, de Goede AL, Berrien-Elliott MM, van der Meer JMR, Mousset CM, Roeven MWH, Foster M, Blijlevens N, Hobo W, Fehniger TA, Jansen JH, Schaap NPM, Dolstra H. de Jonge PKJD, et al. Among authors: fehniger ta. Cancer Immunol Immunother. 2023 Oct;72(10):3323-3335. doi: 10.1007/s00262-023-03492-6. Epub 2023 Jul 21. Cancer Immunol Immunother. 2023. PMID: 37477653 Free PMC article.
Memory-like differentiation enhances NK cell responses against colorectal cancer.
Marin ND, Becker-Hapak M, Song WM, Alayo QA, Marsala L, Sonnek N, Berrien-Elliott MM, Foster M, Foltz JA, Tran J, Wong P, Cubitt CC, Pence P, Hwang K, Zhou AY, Jacobs MT, Schappe T, Russler-Germain DA, Fields RC, Ciorba MA, Fehniger TA. Marin ND, et al. Among authors: fehniger ta. Oncoimmunology. 2024 May 7;13(1):2348254. doi: 10.1080/2162402X.2024.2348254. eCollection 2024. Oncoimmunology. 2024. PMID: 38737793 Free PMC article.
Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma.
Ramirez CA, Becker-Hapak M, Singhal K, Russler-Germain DA, Frenkel F, Barnell EK, McClain E, Desai S, Schappe T, Onyeador OC, Kudryashova O, Belousov V, Bagaev A, Ocheredko E, Kiwala S, Hundal J, Skidmore ZL, Watkins MP, Mooney TB, Walker J, Krysiak K, Gomez F, Fronick CC, Fulton RS, Schreiber RD, Mehta-Shah N, Cashen AF, Kahl BS, Ataullakhanov R, Bartlett NL, Griffith M, Griffith OL, Fehniger TA. Ramirez CA, et al. Among authors: fehniger ta. Blood Adv. 2024 May 7:bloodadvances.2022007792. doi: 10.1182/bloodadvances.2022007792. Online ahead of print. Blood Adv. 2024. PMID: 38713894
Fat matters for natural killer cell activity.
Wong P, Fehniger TA. Wong P, et al. Among authors: fehniger ta. Nat Immunol. 2024 May;25(5):728-730. doi: 10.1038/s41590-024-01825-w. Nat Immunol. 2024. PMID: 38637666 No abstract available.
Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers.
Pizzato HA, Alonso-Guallart P, Woods J, Johannesson B, Connelly JP, Fehniger TA, Atkinson JP, Pruett-Miller SM, Monsma FJ Jr, Bhattacharya D. Pizzato HA, et al. Among authors: fehniger ta. Stem Cell Reports. 2024 Apr 9;19(4):596. doi: 10.1016/j.stemcr.2024.03.006. Epub 2024 Mar 21. Stem Cell Reports. 2024. PMID: 38518782 Free PMC article. No abstract available.
148 results